1. Migraine Therapeutics in Development

2. Migraine Pathophysiology

3. First Targeted Acute Therapy Approved for Migraine The Triptans

4. Sumatriptan 10 mg With a Permeation Enhancer Phase 2 Study

5. Sumatriptan 10 mg With a Permeation Enhancer Freedom From MBS

6. Adhesive Dermally Applied Microarray

7. ADAM Zolmitriptan

8. ADAM Zolmitriptan Freedom From MBS

9. ADAM Zolmitriptan Safety

10. The Role of Serotonin in Migraine Lasmiditan

11. Lasmiditan SAMURAI and SPARTAN Phase 3 Studies

12. Lasmiditan Safety

13. Calcitonin Gene-Related Peptide

14. CGRP Role in Migraine Pathogenesis

15. CGRP-Receptor Antagonists GEPANTs

16. Rimegepant Study 302, Phase 3 Study Design

17. Rimegepant Study 302 Primary Endpoints

18. Rimegepant Study 302 Secondary Endpoints

19. Rimegepant Safety

20. Ubrogepant ACHIEVE II, Phase 3 Study

21. Ubrogepant ACHIEVE II Primary Endpoints

22. Ubrogepant ACHIEVE II Secondary Endpoints

23. Ubrogepant Safety

24. Conclusions

25. Abbreviations

26. Abbreviations (cont)